Jul. 13 at 8:34 PM
$AUTL if anyone thinks this decline is related to anything new with AUTL get a reality check. nothing has changed. the decline is 100% related to XBI selling off nothing else. the problem is when XBI moved higher AUTL was not doing anything. now that bio's are selling off, the algo shorts are jumping in. this talk about dilution is complete nonsense and nothing new. By the way when a bio is already in a late stages of trials dilution doesnt automatically mean a SP decline. In addition AUTL also has revenue, so revenue plus new product to market will be a much different scenario than a bio in early stages raising cash. they dont need to have cash to last all the way to the finish line, just need to get close enough because any approval for a new treatment is Billions in revenue not Millions so that is factored in and there is no way the valuation will be
$400M. there are also other options on raising money at that point.
